Adequate prediction of tumor response to neoadjuvant chemoradiotherapy (nCRT) in esophageal cancer (EC) patients is important in a more personalized treatment. The current best clinical method to predict pathologic complete response is SUVmax in F-18-FDG PET/ CT imaging. To improve the prediction of response, we constructed a model to predict complete response to nCRT in EC based on pretreatment clinical parameters and F-18-FDG PET/CT-derived textural features. Methods: From a prospectively maintained single institution database, we reviewed 97 consecutive patients with locally advanced EC and a pretreatment F-18-FDG PET/CT scan between 2009 and 2015. All patients were treated with nCRT (carboplatin/paclitaxe1/41.4 Gy) followed by esophagec...
Background: Approximately 26% of esophageal cancer (EC) patients do not respond to neoadjuvant chemo...
Aim of this study was to validate the prognostic impact of clinical parameters and baseline 18F-FDG-...
Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. Objective To investigate the role...
Adequate prediction of tumor response to neoadjuvant chemoradiotherapy (nCRT) in esophageal cancer (...
Adequate prediction of tumor response to neoadjuvant chemoradiotherapy (nCRT) in esophageal cancer (...
Adequate prediction of tumor response to neoadjuvant chemoradiotherapy (nCRT) in esophageal cancer (...
Adequate prediction of tumor response to neoadjuvant chemoradiotherapy (nCRT) in esophageal cancer (...
Purpose To assess the value of baseline and restaging fluorine 18 (18F) fluorodeoxyglucose (FDG) pos...
Purpose: To assess the value of baseline and restaging fluorine 18 (F-18) fluorodeoxyglucose (FDG) p...
PURPOSE: Accurate preoperative prediction of pathologic response to neoadjuvant chemoradiotherapy (n...
Background: Approximately 26% of esophageal cancer (EC) patients do not respond to neoadjuvant chemo...
Abstract Background Nearly one third of patients undergoing neoadjuvant chemoradiotherapy (nCRT) for...
BACKGROUND: Approximately 26% of esophageal cancer (EC) patients do not respond to neoadjuvant chemo...
BackgroundNearly one third of patients undergoing neoadjuvant chemoradiotherapy (nCRT) for locally a...
Purpose: To assess the value of baseline and restaging fluorine 18 (F-18) fluorodeoxyglucose (FDG) p...
Background: Approximately 26% of esophageal cancer (EC) patients do not respond to neoadjuvant chemo...
Aim of this study was to validate the prognostic impact of clinical parameters and baseline 18F-FDG-...
Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. Objective To investigate the role...
Adequate prediction of tumor response to neoadjuvant chemoradiotherapy (nCRT) in esophageal cancer (...
Adequate prediction of tumor response to neoadjuvant chemoradiotherapy (nCRT) in esophageal cancer (...
Adequate prediction of tumor response to neoadjuvant chemoradiotherapy (nCRT) in esophageal cancer (...
Adequate prediction of tumor response to neoadjuvant chemoradiotherapy (nCRT) in esophageal cancer (...
Purpose To assess the value of baseline and restaging fluorine 18 (18F) fluorodeoxyglucose (FDG) pos...
Purpose: To assess the value of baseline and restaging fluorine 18 (F-18) fluorodeoxyglucose (FDG) p...
PURPOSE: Accurate preoperative prediction of pathologic response to neoadjuvant chemoradiotherapy (n...
Background: Approximately 26% of esophageal cancer (EC) patients do not respond to neoadjuvant chemo...
Abstract Background Nearly one third of patients undergoing neoadjuvant chemoradiotherapy (nCRT) for...
BACKGROUND: Approximately 26% of esophageal cancer (EC) patients do not respond to neoadjuvant chemo...
BackgroundNearly one third of patients undergoing neoadjuvant chemoradiotherapy (nCRT) for locally a...
Purpose: To assess the value of baseline and restaging fluorine 18 (F-18) fluorodeoxyglucose (FDG) p...
Background: Approximately 26% of esophageal cancer (EC) patients do not respond to neoadjuvant chemo...
Aim of this study was to validate the prognostic impact of clinical parameters and baseline 18F-FDG-...
Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. Objective To investigate the role...